Oxipit Secures Brazilian ANVISA Clearance for ChestEye AI Suite
The regulatory approval paves the way for ChestEye deployments in the Brazilian market. The application is already cleared for use in Europe and Australia. The Brazilian Health Regulatory Agency’s approval is one of Oxipit steps to increase global reach for company products. - February 17, 2023
Oxipit Closes $4.9M Funding Round to Advance AI Autonomy in Medical Imaging
AI medical imaging company Oxipit closed a $4.9M funding round led by Taiwania Capital, Practica Capital, and Coinvest Capital. Angel investors also participated in this round. The funding will help Oxipit advance its development of autonomous AI medical imaging applications and support market expansion into new geographic regions, with particular focus on the United Kingdom. - January 22, 2023
Oxipit Introduces Quality Assurance for MSK, MG, and CT Modalities
AI medical imaging company Oxipit expanded its Quality product suite with quality assurance support for musculoskeletal X-rays, mammography images and lung CT scans. Previously supporting only chest X-rays, the upgraded Quality suite aims to answer all imaging department quality assurance needs with a single product. The updated Quality product will be showcased at RSNA 2022 annual meeting later this month. - November 23, 2022
Kaunas City Polyclinic Picks ChestLink to Speed Up Preventative Health Checks
Kaunas city polyclinic introduced Oxipit ChestLink AI application in their preventive health check up workflow. With ChestLink, which can automatically identify normal chest X-rays, healthy patients can be instantly sent home after the examination, without the need to wait for the study report at the polyclinic. Operating with 99.9% sensitivity, ChestLink can automatically report on 26% of all X-ray studies at Kaunas city polyclinic. - September 30, 2022
Oxipit Study: 1 in 552 CXR Studies Feature Clinically Significant Diagnostic Errors
Oxipit has conducted a retrospective validation study from collected internal data of ChestEye Quality performance at more than 10 pilot deployment institutions. The study concludes that 1 in 552 (0.18%) chest X-ray studies reported by a radiologist include clinically significant diagnostic mistakes. The vast majority - 78.46% - of the errors are missed findings of pulmonary nodules and lymphadenopathy. - July 20, 2022
Chest Experts Oxipit and contextflow Team Up for Diagnostic Quality Assurance
The new partnership aims to mitigate the risk associated with missed findings in CT medical imaging studies. The collaboration will combine Oxipit’s ChestEye Quality and contextflow’s SEARCH Lung CT products to identify missed findings in CT scans in near-real time. ECR 2022 will offer the first preview of the combined solution, and the first installation will be deployed at Leiden University Medical Center. - July 20, 2022
Oxipit Chestlink Autonomous AI Application Misses No Critical Findings in Real-World Clinical Test
Following the CE certification of the first autonomous AI medical imaging application ChestLink, researchers in Finland released a preprint of a study on the application performance. In the study, the application analyzed 10,000 chest X-rays of Finnish primary health care patients. ChestLink software was able to identify normal studies with 99.8% sensitivity and and specificity of 36.4% without any critical findings missed by the software. - July 18, 2022
Oxipit Awarded CE Mark for the First Autonomous AI Medical Imaging Application
AI medical imaging application developer Oxipit was granted CE Class IIb certification for ChestLink autonomous AI imaging suite. The application autonomously reports on chest X-rays featuring no abnormalities without any involvement from a radiologist. It is the first regulatory approved AI medical imaging application to perform diagnostics autonomously. - March 31, 2022
Oxipit to Offer Free of Charge Retrospective CXR Quality Audit at RSNA
At the annual RSNA meeting, the AI medical imaging company will present the new ChestEye Quality AI double reading tool. To showcase vanguard ChestEye Quality capabilities, Oxipit will offer a free-of-charge quality audit for 6 months of retrospective CXR data. - November 26, 2021
Oxipit Expands Executive Team with a New Chief Commercial Officer
AI medical imaging company Oxipit appointed Dany Chammas as their new Chief Commercial Officer. With more than 15 years of experience in top tier medical imaging companies, Dany will join the Executive Team to increase Oxipit’s visibility and accelerate business growth. - October 07, 2021
Oxipit to Preview First Autonomous AI Medical Imaging Application at ECR
The AI medical imaging company will showcase the first autonomous AI diagnostics application for healthy patient report automation. The new product by Oxipit automatically identifies chest X-ray images with no abnormality and produces finalized patient reports without any intervention from the radiologist. The application is pending CE mark certification and will be made available for commercial deployments in the Q3 2021. - March 04, 2021
Oxipit and Parasmed Partnership to Extend CXR AI Product Distribution in Eastern Africa
Medical imaging company Oxipit announced partnership with Parasmed, a Nairobi-based medical healthcare solutions distributor in Eastern Africa. With recent partnerships in Nigeria and strong foothold in Latin America, the new agreement is an important step towards creating a global, locally present network of Oxipit software distributors. - January 14, 2021
Teleradiología de Colombia Partners with Oxipit for Chest X-Ray AI Diagnostics
Teleradiologia de Colombia, a leading diagnostic imaging services provider in Latin America, is rolling out Oxipit AI solutions across its network. Oxipit AI suite will produce preliminary chest X-Ray reports and identify healthy patient images with no abnormalities, augmenting radiologist productivity and improving radiologist workflow. It marks the first Oxipit deployment in Colombia with more announcements in Latin America coming soon. - August 26, 2020
Oxipit Receives Patent for Improved AI Lung Cancer Diagnostics
Oxipit, creators of artificial intelligence based radiology imaging suite ChestEye, announces that the European Patent Office has approved their patent application. The innovation allows efficient use of high-resolution chest X-ray images for machine learning model training and is especially relevant for improving lung nodule detection. - May 27, 2020
Oxipit ChestEye Secures Medical Device Certification in Australia
The AI medical imaging company has received an Australian Register of Therapeutic Goods Class IIa medical device certificate for ChestEye AI imaging service. Medical device certification paves the way for clinical use of ChestEye in the Australian market. ChestEye imaging suite is already certified by the CE mark. Oxipit received CE certification last February, enabling clinical ChestEye deployment in 32 European countries. - March 07, 2020
New Oxipit Service to Aid Large Scale Chest X-Ray Screening Projects
The AI medical imaging company will showcase ChestEye Negative service at Arab Health 2020 conference in Dubai. ChestEye Negative produces preliminary reports for chest X-rays with no abnormality. The service aims to reduce the workload of radiologists, especially in clinical environments, where only a fraction of all studies features an abnormality. It also significantly simplifies large-scale medical screening projects. - January 31, 2020
Oxipit to Showcase AI X-Ray Longitudinal Comparison at RSNA
The AI medical imaging company will offer a first public preview of Dynamics feature for its award winning ChestEye CAD suite. Dynamics enables a radiologist to compare X-rays and provide automatically generated reports specifically addressing the changes in images over the course of patient treatment. - December 08, 2019
Study: AI Found to Reduce Bias in Radiology Reports
A study by the Centre for Advanced Research in Imaging, Neuroscience and Genomics (CARING) found that AI powered CAD software can reduce hedging and defensive reporting statements in radiologist reports, resulting in clearer more actionable diagnosis descriptions. The study was undertaken using Oxipit ChestEye AI imaging suite. - November 28, 2019
Medical Imaging Company Oxipit Raises $1.7m Seed Round to Bring AI Into Clinical Radiology Practice
Oxipit are the authors of ChestEye AI-powered radiology software suite. Automated AI-based diagnosis and reporting by ChestEye enables radiologists to improve productivity, reduce error-rate, discover overlooked secondary findings and address the shortage and ever-increasing workload of radiology specialists. - July 24, 2019